Fundraising Fox

ProQR

3 known investors

ProQR Therapeutics develops RNA editing therapies for patients with genetic disorders through its proprietary Axiomer RNA editing platform. The company conducts drug discovery and development, including a partnership with Eli Lilly and Company for new medicines.

BiotechHealthtech

Investors · 3

Invivo Capital PartnersBarcelona · $2.2M – $4.3M
Pontifax Venture CapitalHerzeliya · $6.3M – $128M
Sofinnova PartnersParis · $540K – $27M

In the news

ProQR Establishes First Clinical Validation Of Axiomer Platform; AX-0811 Data Due By Year-Endrttnews.com · Aug 2026BofA Securities initiates ProQR stock with buy on liver therapy By Investing.cominvesting.com · Aug 2026Bank of America Initiates Coverage on ProQR Therapeutics (NASDAQ:PRQR) - Ticker Reporttickerreport.com · Aug 2026HC Wainwright Expects Lower Earnings for ProQR Therapeuticsmarketbeat.com · Aug 2026ProQR Raises $59 Million in Equity Offering and Eli Lilly Private Placement - The Globe and Mailtheglobeandmail.com · Jun 2026ProQR raises $50M as Lilly joins a $9.2M share buystocktitan.net · Jun 2026

Frequently asked questions

What does ProQR do?
ProQR Therapeutics develops RNA editing therapies for patients with genetic disorders through its proprietary Axiomer RNA editing platform. The company conducts drug discovery and development, including a partnership with Eli Lilly and Company for new medicines.
Who are ProQR's investors?
ProQR's investors include Invivo Capital Partners, Pontifax Venture Capital, Sofinnova Partners.